Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model

Background: Ulcerative colitis (UC) is an autoimmune disorder characterized by inflammation of the mucosa that gives rise to a disrupted epithelial morphology. Persistent or recurrent inflammation and the debilitating nature of the associated symptoms make treatment of UC challenging. Cannabinoids derived from Cannabis sativa L. have been used for treatment of gastrointestinal disorders due to the wide-ranging therapeutic benefits of these compounds. Methods: We evaluated a commercial hemp extract, high in cannabigerol (CBG) and cannabidiol (CBD), as a novel treatment for UC symptoms using the dextran sodium sulfate (DSS) model in mice. Hemp extract was administered via two different routes of administration, intraperitoneal (i.p) and oral (p.o). Results: Specifically, we observed that cannabinoid treatment reduced damage to the colonic epithelium. We also observed that CBG/CBD rich hemp extracts help reduce pain-related responses in these animals. Conclusions: Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management.

• Publication year

  2025

• Venue

  Journal of Clinical Medicine

• Publication date

  2025-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/jcm14176095PMID 40943856PMCID 12429149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Machine learning in the differential diagnosis of ulcerative colitis and Crohn’s disease: a systematic review

  2025cited by this paper
• Current and Emerging Autoantibodies in Ulcerative Colitis

  2025cited by this paper
• Therapeutic Potentials of Phytochemicals in the Treatment of Ulcerative Colitis: Results from Animal Model Interventional Studies.

  2025cited by this paper
• Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation.

  2025cited by this paper
• The role of diet in inflammatory bowel disease: A comprehensive review of the literature.

  2025cited by this paper
• Pharmacokinetics of Non-Psychotropic Phytocannabinoids

  2025cited by this paper
• Treatment targets in IBD: is it time for new strategies?

  2025cited by this paper
• Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.

  2024cited by this paper
• Mucin Expression Profiles in Ulcerative Colitis: New Insights on the Histological Mucosal Healing

  2024cited by this paper
• Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential

  2024cited by this paper
• Novel targets for mucosal healing in inflammatory bowel disease therapy.

  2024cited by this paper
• Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain

  2024cited by this paper
• Activation of CB2 Receptors by (−)-Cannabichromene but Not (+)-Cannabichromene

  2024cited by this paper
• High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model

  2024influential reference
• Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development

  2024cited by this paper
• CANNABINOIDS AND NEUROINFLAMMATION: THERAPEUTIC IMPLICATIONS

  2023cited by this paper
• Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests

  2023cited by this paper
• Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial

  2023cited by this paper
• Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.

  2023cited by this paper
• Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review

  2023cited by this paper
• Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics that Effectively Manage Bone Fracture Pain and Promote Healing in Mice

  2023cited by this paper
• The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study.

  2023cited by this paper
• Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants

  2023cited by this paper
• The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature

  2023cited by this paper
• Medical Cannabis for Chronic Nonmalignant Pain Management

  2023cited by this paper
• Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts

  2023cited by this paper
• The antinociceptive activity and mechanism of action of cannabigerol.

  2023cited by this paper
• Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action

  2022cited by this paper
• Somatosensory assessments in patients with inflammatory bowel disease: a cross-sectional study examining pain processing pathways and the role of multiple patient factors

  2022cited by this paper
• Differences in the Perception of Dietary Supplements between Dietary Supplement/Medicine Users and Non-Users

  2022cited by this paper
• Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy‐induced peripheral neuropathy

  2022cited by this paper
• Strategies for enhancing the oral bioavailability of cannabinoids

  2022cited by this paper
• Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease

  2022cited by this paper
• Chronic Inflammation in Ulcerative Colitis Causes Long-Term Changes in Goblet Cell Function

  2021cited by this paper
• Cytochrome P450–Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

  2021cited by this paper
• The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.

  2021cited by this paper
• Symptoms and Extraintestinal Manifestations in Active Cannabis Users with Inflammatory Bowel Disease

  2021cited by this paper
• Antinociceptive effects of minor cannabinoids, terpenes and flavonoids in Cannabis

  2021cited by this paper
• Cannabidiol-Driven Alterations to Inflammatory Protein Landscape of Lipopolysaccharide-Activated Macrophages In Vitro May Be Mediated by Autophagy and Oxidative Stress

  2021cited by this paper
• Mucins Dynamics in Physiological and Pathological Conditions

  2021cited by this paper
• Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review

  2021cited by this paper
• Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption

  2021cited by this paper
• Intestinal inflammation-associated hypersensitivity is attenuated in a DSS model of colitis in Sigma-1 knockout C57BL/6 mice.

  2021cited by this paper
• Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease

  2021cited by this paper
• Abdominal pain in quiescent inflammatory bowel disease

  2020cited by this paper
• Cannabis for the Treatment of Inflammatory Bowel Disease: A True Medicine or a False Promise?

  2020cited by this paper
• Cannabidiol

  2020cited by this paper
• Dietary supplements - use and safety perception: A study among hospitalized dermatology patients.

  2020cited by this paper
• Mechanisms of Action and Pharmacokinetics of Cannabis.

  2020cited by this paper
• Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.

  2019cited by this paper
• Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts.

  2019cited by this paper
• Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?

  2019cited by this paper
• Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence

  2019cited by this paper
• A comprehensive review and update on ulcerative colitis.

  2019cited by this paper
• DMH‐CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF‐kB activity dependent on A2A receptor

  2019cited by this paper
• The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

  2018cited by this paper
• Patients’ perceptions and use of natural health products

  2018cited by this paper
• Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

  2018cited by this paper
• Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors

  2018cited by this paper
• Cannabis-based medicines for chronic neuropathic pain in adults.

  2018cited by this paper
• Cannabichromene is a cannabinoid CB2 receptor agonist

  2018cited by this paper
• Cannabis, Cannabinoids, and the Endocannabinoid System—Is there Therapeutic Potential for Inflammatory Bowel Disease?

  2018cited by this paper
• Use of Medical Cannabis in Patients With Inflammatory Bowel Disease.

  2018cited by this paper
• CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity

  2017cited by this paper
• An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse

  2016cited by this paper
• Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

  2016cited by this paper
• A qualitative insight on complementary and alternative medicines used by hypertensive patients

  2016cited by this paper
• A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice

  2016cited by this paper
• Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy

  2016cited by this paper
• Dextran Sulfate Sodium (DSS)‐Induced Colitis in Mice

  2014cited by this paper
• Understanding and targeting centrally mediated visceral pain in inflammatory bowel disease

  2014cited by this paper
• Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.

  2013cited by this paper
• The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis

  2013cited by this paper
• The Myc 3′ Wnt Responsive Element Regulates Neutrophil Recruitment After Acute Colonic Injury in Mice

  2013cited by this paper
• Inhibitory effect of cannabichromene, a major non‐psychotropic cannabinoid extracted from Cannabis sativa, on inflammation‐induced hypermotility in mice

  2012cited by this paper
• The Myc 3′ Wnt-Responsive Element Regulates Homeostasis and Regeneration in the Mouse Intestinal Tract

  2012cited by this paper
• Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour

  2011cited by this paper
• Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.

  2010cited by this paper
• A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells.

  2009cited by this paper
• Use and Safety Perceptions Regarding Herbal Supplements: A Study of Older Persons in Southeast Idaho

  2009cited by this paper
• Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

  2009cited by this paper
• Cannabinoids as novel anti-inflammatory drugs.

  2009cited by this paper
• Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation

  2009cited by this paper
• Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products.

  2007cited by this paper
• Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

  2005cited by this paper
• Agonistic Properties of Cannabidiol at 5-HT1a Receptors

  2005cited by this paper
• Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging.

  2001cited by this paper
• A new model of visceral pain and referred hyperalgesia in the mouse

  2001cited by this paper
• Cannabinoids modulate pain by multiple mechanisms of action

  2000cited by this paper
• Assessment of Patients' Perceptions and Beliefs Regarding Herbal Therapies

  2000cited by this paper
• Pharmacology of cannabinoid receptors.

  1995cited by this paper
• Hormonal Regulation of the Release of Plasminogen Activators and of a Specific Activator Inhibitor from Endometrial Tissue in Culture

  1986cited by this paper
• [Ulcerative colitis].

  1958cited by this paper

• The dual roles of natural cannabidiol in combating oxidative stress and inflammation: A potential intestinal guardian.

  2026cites this paper
• Nanoencapsulated Cannabidiol–Cannabigerol Using Eudragit L100: In Vitro and In Vivo Evidence in Murine Colitis Model

  2026cites this paper